INTC vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Intel Corp. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Intel Corp. · Technology
$107.76
-5.2% upside to fair value
Grade D
VS
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
QuantHub Verdict
INTC has more upside to fair value
(-5.2%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
JNJ |
| Current Price |
$107.76 |
$253.85 |
| Fair Value Estimate |
$102.16 |
$198.76 |
| Upside to Fair Value |
-5.2%
|
-21.7%
|
| Market Cap |
$541.6B |
$611.1B |
| Forward P/E |
-173.8x
|
29.3x
|
| EV / EBITDA |
49.9x
|
19.2x
|
| Price / Sales |
10.1x
|
6.3x
|
| Price / FCF |
-173.7x
|
34.3x
|
| Revenue Growth YoY |
+7.2%
|
+9.9%
|
| Gross Margin |
35.4%
|
69.1%
|
| Operating Margin |
-9.4%
|
26.9%
|
| Return on Equity |
-3.0%
|
26.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
2.91%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Intel Corporation is a leading semiconductor company operating in the technology sector, specializing in designing and manufacturing microprocessors and related technologies. The business quality is currently low due to negative earnings growth of 354.1% in the most recent quarter and negative profitability metrics including a net margin of -5.9% and an operating margin of -9.4%. Despite a revenu…
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Accumulation Zones
| Metric |
INTC |
JNJ |
| Zone Low |
$76.62 |
$149.07 |
| Zone High |
$86.84 |
$168.95 |
| In Buy Zone? |
No
|
No
|